Zhejiang Medicaine

Zhejiang Medicaine is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the development of innovative therapies for ophthalmic diseases. As a subsidiary of the publicly traded Zhejiang Medicaine Technology Group, the company leverages advanced protein engineering and multi-specific antibody platforms to create next-generation biologics. Its lead candidate, MDK-101, is a bispecific antibody targeting both VEGF and ANG-2, currently undergoing Phase 1/2 clinical trials for neovascular age-related macular degeneration and diabetic macular edema. The company's pipeline also includes early-stage programs for dry age-related macular degeneration and geographic atrophy, utilizing both large and small molecule modalities. Zhejiang Medicaine aims to address significant unmet needs in retinal health by providing long-acting and highly effective treatment options. The company represents a strategic expansion of its parent group into the high-barrier life sciences sector.